Incorporating Teclistamab in R/R MM: Insights from Clinical Practices Across the US
Expert hematologist-oncologists discuss how they incorporate teclistamab in their clinical practice as well as variations in access to bispecifics and CAR T-cell therapy.
EP: 1.Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)
EP: 2.Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM Treatment
EP: 3.MonumenTAL-1: Evaluating the Anti- GPRC5D-Targetings Bispecific in R/R MM
EP: 4.FCRH5-Targeting and Other Emerging Bispecifics in R/R MM
Now Viewing
EP: 5.Incorporating Teclistamab in R/R MM: Insights from Clinical Practices Across the US
EP: 6.Step-up Dosing and Monitoring in Patients with MM on Bispecifics: Health System Perspectives
EP: 7.Best Practices for Transition of Care in Patients with MM on Teclistamab
EP: 8.Managing Infections and Other Toxicities Associated with Bispecifics in MM
EP: 9.Sequencing BCMA-Targeting Bispecifics in R/R MM Treatment
EP: 10.Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment
EP: 11.Future Perspectives on the Role of Bispecifics in MM
EP: 12.Key Takeaways from Health Care Systems on the Role of Bispecifics in MM
EP: 13.Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma
EP: 14.Treatment Recommendations for Relapsed Multiple Myeloma
Recent Videos
Related Content
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024Podcast
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
